Showing results (3141-3150 of 3,717) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|October 28, 2003
A phase II trial of pemetrexed in patients with metastatic renal cancerR Thödtmann, T Sauter, S Weinknecht, et al.Investigational New Drugs|October 28, 2003
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group StudyDeborah K Armstrong, John A Blessing, Katherine Y Look, et al.Investigational New Drugs|July 1, 1992
Menogaril in the treatment of malignant mesothelioma: a phase II studyC A Hudis, D P KelsenInvestigational New Drugs|August 1, 1992
Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center studyL J Kilton, A B Benson, A Greenberg, et al.Investigational New Drugs|August 1, 1992
Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinomaE S Casper, G K Schwartz, D P KelsenInvestigational New Drugs|October 31, 2003
In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176Manabu Takagi, Takuya Honmura, Shuuji Watanabe, et al.Investigational New Drugs|October 31, 2003
Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cellsFederica Barbieri, Angela Alama, Bruno Tasso, et al.Investigational New Drugs|October 31, 2003
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanesRosa Sánchez, Emilio Esteban, Isabel Palacio, et al.Investigational New Drugs|October 31, 2003
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancerMaha Hussain, Ulka Vaishampayan, Lance K Heilbrun, et al.Investigational New Drugs|November 1, 1992
Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancerL Kayitalire, F Thomas, T Le Chevalier, et al.Pageof 372